Skip to main content

VitalCells Releases a Breakdown of Cord Blood Banking Flaws Revealed by New York Times, Offering Real Solutions in Stem Cell Banking

Sunrise, FL - In response to the recent New York Times articles exposing the significant shortcomings of traditional cord blood banks, VitalCells is setting a new industry standard by providing parents with live mesenchymal stem cells (MSCs) from their newborn's umbilical cord tissue and blood. This innovative approach ensures families have tangible, usable stem cells for regenerative medicine, addressing the critical issues highlighted in the exposé.

The recently published New York Times articles, "Promised Cures, Tainted Cells: How Cord Blood Banks Mislead Parents" and "What Parents Should Know About Cord Blood Banking," by Sarah Kliff and Azeen Ghorayshi, Dr. Robert Brodsky of Johns Hopkins University point out that cord blood is not typically the preferred source of stem cells due to its limited quantity and usability. 

Moreover, investigations by The New York Times have shed light on significant issues within the industry, including misleading claims about cell counts, contamination problems, and restrictions on the types of medical treatments for which these cells can be used. Many parents have been disappointed to discover that their stored cells are not viable for treatments they hoped to pursue, such as therapies for autism or cerebral palsy. Confirmed by research and other expert opinions, traditional cord blood banking may not be as reliable or beneficial as once thought.

In response to these limitations, a new approach has emerged: personal stem cell banking. Unlike traditional cord blood banks, which focus on storing cells for potential unrelated donors in transplantation purposes for rare medical conditions, personal stem cell banks like VitalCells prioritize storing a child's own (autologous) stem cells for personal use in conjunction with their medical practitioner for potentially more common uses. This ensures the cells are a perfect match and can be used throughout their lifetime with their medical practitioner.

Regarding the issue of insufficient cells in the sample, where attempts to withdraw are often deemed unusable due to low cell count, VitalCells culture expands these autologous cells upon retrieval. If they cannot obtain at least 10 million mesenchymal stem cells initially, clients are refunded. This process ensures 5x-10x more live cells than those natively available in cord blood/tissue samples, potentially generating billions of live cells throughout the child’s life.

To address the concern of clients paying for contaminated samples, VitalCells mandates that every sample must pass stringent sterility and contamination protocols to ensure the child’s cells are usable in the future. A contamination screening is performed upon receiving samples, and clients are refunded if samples are found contaminated.

Finally, in response to the limitation on the reasons for cell release (transplant or clinical trials approved by the FDA), at VitalCells, the cells belong to the clients and are used in conjunction with their medical practitioner through the practice of medicine. These autologous cells are not classified as drugs and, therefore, do not require FDA approval.

Dr. Sabrina Solt, a leading expert in regenerative medicine, emphasizes the importance of knowing exactly what families are getting with stem cell banking. She notes that traditional banks often cannot guarantee the quantity or quality of cells available, making it a risky investment for parents seeking a reliable medical resource. 

VitalCells, backed by American Cell Technology, stands out in the field of stem cell banking by addressing the shortcomings of traditional methods. They specialize in isolating and storing mesenchymal stem cells (MSCs) from umbilical cord tissue and blood, ensuring stringent quality control measures to guarantee usability. Unlike traditional banks, VitalCells expands these cells upon retrieval, potentially generating billions of live cells over a child's lifetime. 

Dr. Solt also trusts VitalCells with her own child's future, citing their commitment to transparency and quality. She highlights the peace of mind in knowing that her child's stem cells are not only accessible but also viable for potential medical use without the red tape often associated with traditional banks. 

https://www.youtube.com/watch?v=KtaaPJcJTDo

Visit VitalCells to learn more about their approach to stem cell banking, how they are revolutionizing the industry and ensuring families are making the best choice for their child's future health from the very beginning. 

###

For more information about Vital Cells, contact the company here:

Vital Cells
Korbet Annis
(844) 734-8386
contact@vitalcells.com
13794 NW 4th St STE 212, Sunrise, FL 33325

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.